1.953 hasil
Menampilkan 1–20 · 0,33 detik · RSS
Therapeutic Advances in Medical Oncology
Scopus
ISSN 1758-8340 · SAGE Publishing · 1.953 artikel di indeks
-
Artikel Jurnal
Longitudinal dynamics and recovery of lymphocytes in patients with breast cancer receiving radiotherapy without chemotherapy after breast-conserving surgery: A second analysis of a phase III randomized trial of HYPOfractionation in BREAST radiotherapy for Chinese women (CHN HYPOBREAST)
Background Radiotherapy-induced lymphopenia (RIL) has been associated with inferior clinical outcomes in multiple solid tumors. However, the long-term dynamics and recovery of peripheral lymphocyte counts (PLCs) after radiotherapy remain poorly characterized. Objectives To evaluate the longitudinal…
-
Artikel Jurnal
Clinicopathologic and molecular features of head and neck NUT carcinoma: Analysis of 25 cases, including 5 with adenoid differentiation
Background Nuclear protein in testis (NUT) carcinoma is a highly aggressive malignancy driven by NUTM1 gene fusions, with a median overall survival of 6.5–10.6 months. A comprehensive summary of the morphological and molecular features of head and neck NUT carcinoma is lacking, resulting in…
-
Artikel Jurnal
Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in older adults. Treatment in this population remains challenging due to heightened genetic heterogeneity and reduced physiological reserve, which increase susceptibility to both treatment-related toxicity and…
-
Artikel Jurnal
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis
Background: The evidence from studies comparing 45 and 30 mg starting doses of first-line dacomitinib for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) remains limited. Objectives: This study aimed to compare the clinical efficacy and safety of two…
-
Artikel Jurnal
Exploring the molecular classification-based personalized treatment decision-making in FIGO stage I–III endometrial carcinoma after surgery: a population-based real-world study
Background: Robust real-world evidence supporting the clinical utility of molecular classification in endometrial carcinoma (EC) remains limited. Objectives: To investigate the molecular classification-based personalized treatment decision-making for EC by presenting real-world data, including…
-
Artikel Jurnal
Serum levels of the C-terminal pro-peptide of type V collagen have prognostic potential and are associated with a normal subtype of desmoplasia in a retrospective cohort of patients with esophagogastric cancer
Background: The role of stroma in esophagogastric cancer is ambiguous, with both tumor-promoting and tumor-restrictive properties. Several non-invasive biomarkers of stroma have recently been identified, but their relationship with stromal composition and clinical outcome in esophagogastric cancer…
-
Artikel Jurnal
Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis
Background: Receptor conversion, including changes in human epidermal growth factor receptor 2 (HER2) expression, has been reported after neoadjuvant therapy (NAT), but determinants of HER2 changes between baseline biopsy and residual disease remain incompletely understood. Objective: To evaluate…
-
Artikel Jurnal
Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study
Background: FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) are the main first-line regimens for advanced pancreatic adenocarcinoma. No randomized clinical trials have directly compared their efficacy, and real-world data remain limited. Objectives: The primary endpoint of this study was…
-
Artikel Jurnal
Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) can exhibit striking histologic and immunophenotypic heterogeneity. A 36-year-old woman with uterine leiomyomas presented with a 5.1-cm left renal sinus mass and retroperitoneal adenopathy. Biopsy showed juxtaposed lower-grade oncocytic…
-
Artikel Jurnal
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with amplification: a case report
The Programmed death-ligand 1 (PD-L1) gene amplification has been proposed as a potential predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs); however, its clinical relevance in the setting of ICI rechallenge after resistance to initial ICI therapy remains unclear. We…
-
Artikel Jurnal
Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer
Background: While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics. Objectives: To identify clinical and molecular factors associated with overall survival (OS) in patients…
-
Artikel Jurnal
Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients
Background: The efficacy and safety of adebrelimab plus carboplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) have been investigated in the CAPSTONE-1 study. However, many patients with brain metastases, as well as some with liver…
-
Artikel Jurnal
Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study
Background: Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival. Objectives: We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with…
-
Artikel Jurnal
(Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China
Background: The introduction of pertuzumab in mainland China in 2019 has significantly altered the treatment practice for early breast cancer; however, comprehensive real-world data on hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) patients in this new…
-
Artikel Jurnal
Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians
Extensive stage small cell lung cancer (ES-SCLC) carries a very poor prognosis and has been the focus of intensive research. Targeting cell surface molecules is paying off. Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab in previously treated ES-SCLC generated an…
-
Artikel Jurnal
The efficacy of targeted therapy in ALK-positive non-small-cell lung cancer patients and analysis of MET/PD-L1 expression status
Background: Anaplastic lymphoma kinase-targeted tyrosine kinase inhibitors (ALK-TKIs) have revolutionized the treatment of non-small-cell lung cancer (NSCLC). However, several key issues remain unresolved. Specifically, the impact of prior chemotherapy on ALK-TKI efficacy is unclear, the impact of…
-
Artikel Jurnal
Cytokine release syndrome in solid tumours: mechanism-based therapeutic strategies for prevention and management
Cytokine release syndrome (CRS) represents a spectrum of immune hyperactivation initiated by rapid T-cell engagement and amplified through innate immune cells, particularly monocytes and macrophages, with downstream cytokine cascades driving endothelial dysfunction, capillary leak and organ…
-
Artikel Jurnal
Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study
Background: Although combinations of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy or amivantamab have significantly improved progression-free survival (PFS) and overall survival (OS) compared with EGFR-TKI monotherapy in EGFR -mutated…
-
Artikel Jurnal
Treatment options in platinum-refractory male germ cell cancers: current standards and future directions
Germ cell cancers (GCCs) represent the most common malignant tumours among men up to the age of 40 years. GCCs are characterised by high cure rates of >99% for localised stage I disease, but even at advanced metastatic stages, 67%–96% of patients can be cured with multimodal treatment approaches…
-
Artikel Jurnal
Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data
Background: Although modified FOLFIRINOX (mFOLFIRINOX) has improved survival in patients with resected pancreatic ductal adenocarcinoma (PDAC) in clinical studies, S-1 is also a treatment option with desirable efficacy and limited toxicity. We aimed to compare the efficacy and safety of adjuvant…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.